Steroid refractory acute GVHD (SR aGVHD) is associated with high morbidity and mortality. This study attempted to generate a risk model for SR aGVHD using 259 single nucleotide polymorphisms (SNPs) in 53 genes of recipients and donors. A total of 268 patients with aGVHD who were treated with systemic steroids were included. Patients were randomly divided into training (n = 180) and validation sets (n = 88). Clinical risk factors were also evaluated. In the training set, 85 (47.2%) developed SR aGVHD. Gastrointestinal involvement (P o0.0001) and donor genotypes of IL6 (rs1800797; P = 6.2 × 10 −4 ) and IFNG (rs2069727; P = 4.4 × 10 −4 ) were significant risk factors. Scores were assigned to the above risk factors. Patients were divided into low (score 0, n = 74) vs high risk (scores 1-3; n = 106) in risk model. Higher incidence of SR aGVHD was noted in the high risk (61.3%) vs the low-risk group (27%; P o 0.0001, odds ratio (OR) 4.28). Predictive effect of risk model was replicated in the validation set (P = 0.0045, OR 3.74). This risk model was associated with response to therapy, overall and GVHD-specific survival and non-relapse mortality. Our study suggested that this risk model could identify patients at high risk of SR aGVHD with donor genotype of IL6 (rs1800797) and IFNG (rs2069727) along with gastrointestinal involvement of aGVHD.
INTRODUCTION
Steroid refractory acute GVHD (SR aGVHD) is associated with high morbidity and mortality after hematopoietic cell transplant (HCT) 1, 2 with an incidence of 35-55%. [3] [4] [5] There is a paucity of clinical risk factors that can identify SR aGVHD. Several clinical risk factors have been examined: age, gender, donor type and intensity of conditioning regimens, disease status at HCT, dose of infused CD34+ cells, grade of aGVHD and dose of steroids. 1, 4, 5 However, hyperacute GVHD and grade III-IV aGVHD seem likely factors. 5 There are even fewer data about tests or biomarkers for identifying patients who will not respond to steroids and will need treatment with second-line agents. Given the morbidity and mortality of disease that is not responsive to steroids, it is of high significance that these patients should be identified earlier and treated appropriately. There are some biomarkers that are being explored to predict risk of SR aGVHD. 6 However, since therapeutic options for SR aGVHD are quite limited and may not be very effective once irreversible damage is done, it is imperative that it may be identified early so as the patients can be moved on to second-line options.
Single nucleotide polymorphisms (SNPs) are nucleotide variants of DNA potentially affecting gene expression or function of the gene product. They have been evaluated for association with several diseases including GVHD. [7] [8] [9] [10] Our group has previously shown a risk model using SNPs to predict patients with high risk of developing aGVHD and hence decreased OS. 11 Other studies have also examined SNPs to predict the onset of GVHD, but not their response to steroid therapy or development of SR aGVHD. [12] [13] [14] [15] Given that clinical outcome in SR aGVHD patients is dismal, it is a clinically relevant question if there is a way to predict SR aGVHD even before proceeding to HCT. There might be a chance to select the donor based on SNP information in order to choose the donor with the lowest probability of HCT-related complications in the recipient. Here, we attempt to develop a risk model for prediction of SR aGVHD, evaluating both SNPs and clinical risk factors.
MATERIALS AND METHODS

Patients and transplant characteristics
A total of 268 consecutive patients who received related or unrelated allogeneic HCT between November 1999 and October 2007 at the Princess Margaret Cancer Center, University of Toronto, and developed aGVHD, then treated with systemic steroids were initially enrolled. This study was approved by the Research Ethics Board in the University Health Network.
Inclusion criteria were (1) patients received allogeneic HCT and had confirmed aGVHD treated with systemic steroids; (2) those whose archived DNA samples from donor and recipient were available. Our institutional policies and details of transplant procedures have previously been published. [16] [17] [18] [19] [20] Patients were followed at least twice per week for the first 2 months after HCT. aGVHD was diagnosed and graded using established criteria. 21 The development of each organ aGVHD was retrieved from an in-house BMT database. The definition of SR aGVHD which was used is as follows: (1) progression after 3 days of 2 mg/kg/day of methylprednisolone or equivalent steroid therapy and/or (2) no change after 7 days; and/or (3) incomplete response after 14 days.
We defined the day of initiation of systemic steroid therapy for aGVHD treatment as day 0. Disease risk for HCT was defined as described previously. 23 Non-relapse mortality (NRM) was defined as death not related to disease recurrence or progression. OS was defined as the time from HCT until death from any cause. GVHD-specific survival (GSS) was defined as the time from onset of aGVHD to death from acute or chronic GVHDrelated causes without relapse. 24 There were no competing risk factors for GSS.
Response was retrospectively evaluated. Overall response to steroid therapy was retrospectively evaluated by day 28 and day 56 after starting GVHD therapy per published criteria. 3 If the patient died before day 28 or 56 for response assessment, he/she was censored.
Selection of candidate genotypes for SNP typing
Two hundred and fifty-nine SNPs in the 53 genes were evaluated, based on previously published data, which relate with cytokine pathways (n = 118), NFKB (n = 29), TGF-β (n = 22), PDGF (n = 22), apoptosis (n = 17), Toll-like receptor (n = 14), NOD2/CARD15 (n = 10), prostaglandin-endoperoxide synthase (n = 9), FCGR2A (n = 1) and endothelial nitric oxide regulation (n = 17). 11, [25] [26] [27] [28] Details of these genotypes and their respective allele frequencies in both recipients and donors are provided in Supplementary 
Random division into training and validation sets
Overall population of patients (n = 268) was randomly divided into training (n = 180) and validation sets (n = 88) at a ratio of 2:1 (Supplementary Figure 1) after stratifying based on presence of SR aGVHD, disease risk, grade III-IV aGVHD, presence of gastrointestinal and liver involvement by GVHD. The clinical characteristics and transplant outcomes of training vs validation sets were compared using the chi-square test, Fisher's exact test or the Wilcoxon rank-sum test as appropriate.
Univariate and multivariate analyses using logistic regression model in the training set In the training set (n = 180), univariate analysis was performed for 259 SNPs using a recessive model to explore potential risk factors for SR aGVHD. For multivariate analysis to construct the predictive risk model, a P-value of 0.001 for SNPs was used as a selection criterion and then put in to a multivariable model.
Clinical variables of age ⩾ 50 (categorical), disease risk (low, intermediate and advanced), donor type (matched related vs others), source of stem cells (marrow vs PBSC), conditioning (myeloablative vs reduced intensity), GVHD prophylaxis including alemtuzumab and T-cell depletion, organ involvement including skin, gastrointestinal and liver were assessed as risk factors for development of SR aGVHD. Clinical factors were selected and included if the P-value was o0.05 in the univariate analysis. All P-values were two sided.
The SNPs and clinical variables in the training set were evaluated for association with risk of steroid resistance. On univariate analysis, SNPs (at the level of significance of 0.001) and clinical risk factors (at the level of significance of 0.05) were adjusted for in the multivariate model for these risk factors. They were then evaluated in the validation set.
Odds ratios (OR) and 95% confidence intervals (CIs) for the association of each identified SNP and clinical risk factors for SR aGVHD were calculated. Data analysis was performed using Statistical Analysis Software (SAS) Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Score assignment and generation of risk model using SNPs and clinical risk factors and stratification into high-vs low-risk groups in training set Upon identifying significant genetic risk factors for SR aGVHD, a score of 1 was assigned for each of these genetic risk factors. Similarly, each significant clinical risk factor was given a score of 1. Hence, patients with the absence of any risk factor had a score of 0. For multiple risk factors, patients with only one risk factor received a score of 1, two with a score of 2 and three with score of 3. Thus, based on the identified risk, about one third of patients had a score of 0, and were considered low risk. Alternatively, the score of 1-3 was considered high risk leading to the generation of our risk model. In this way, the samples were divided into low-and high-risk groups. Finally, the rate of SR aGVHD was calculated according to each risk group.
Validation of risk model in the validation dataset
In the validation step, we verified the predictive effect of this risk model on SR aGVHD using the independent validation set of 88 patients' data.
Sensitivity and specificity of risk model
Additional statistics were generated such as sensitivity, specificity, positive predictive value and negative predictive value to compare the different models. Area under the curve (AUC) from the model was calculated using logistic regression.
Overall response rate at day 28/56 by risk model
Overall response rate to aGVHD therapy was also compared by day 28 and day 56 as per previously published criteria. 3 We also assessed if this risk model correlated with response to therapy.
NRM, GVHD specific and OS by risk model
Exploratory analysis was conducted on NRM, GSS and OS that were defined above comparing low-vs high-risk patients by risk model using EZR (http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html). 29 These are shown in Figure 1 as the overall flow of the study.
RESULTS
Patient characteristics
A total of 268 patients were enrolled based on inclusion criteria as described above. Baseline characteristics are summarized in Table 1 . Overall, 125 (47%) patients developed SR aGVHD and they were equally distributed in training and validation sets (Table 1 ). There was no significant difference in demographic and transplant characteristics between the two groups. The median follow-up for our study was 17.1 (range 0.49-77) months.
SNP risk factors for SR aGVHD on univariate analysis
We examined 259 SNPs in 53 genes as described above by univariate analysis. Detailed results are presented in Supplementary Tables 1A and B. Out of 259 SNPs in recipients, P-value o 0.05 was seen in six, 0.01 in three and 0.001 in no SNPs. However, among donor genotypes, P-value o 0.05 was seen in 12, 0.01 in 2 and 0.001 was seen in 2 SNPs. Based on our study criteria for SNPs of P-value o0.001, these two SNPs were selected. Hence, donor IL6 (rs1800797; P = 6.2 × 10 ) were found to be significantly associated with risk for SR aGVHD (Table 2A) .
In summary, the patients who received HCT from donors with genotype IL6 (rs1800797) had a 2.8-fold increase in risk of SR aGVHD compared to those with absence of this genotype, while those with donor IFNG (rs2069727) genotype had a 2.9-fold increase in risk of SR aGVHD compared to those with absence of this genotype.
We evaluated risk of relapse with these genotypes. Among 77 patients with 0 G allele with IFNG which was the risk allele 17 patients relapsed (22%), while among 191 patient with 1 or 2 G allele 36 (19%) relapsed, (P = 0.548, 95% CI 0.428-1.569). Similarly for IL6, 120 patients had 0 A allele of whom 24 (20%) relapsed, while 148 patients had 1 or 2 A alleles of whom 29 (20%) relapsed (P = 0.934, 95% CI 0.629-1.657).
When other outcomes to individual SNPs were examined, neither donor IL6 (rs1800797) nor donor IFNG (rs2069727) correlated with either OS or NRM. However, when response to steroids at day 28 was evaluated donor IFNG (rs2069727) Abbreviations: aGVHD = acute GVHD; GI = gastrointestinal; PBSC = peripheral blood stem cells; pt = patient; SR aGVHD = steroid refractory aGVHD; yrs = years.
SNP as SR aGVHD risk N Alam et al correlated with statistically higher response in the 0 allele group, while this was not seen with donor IL6 (rs1800797).
Clinical risk factors for SR aGVHD When clinical risk factors (as described in the Materials and Methods section) were evaluated, gastrointestinal involvement of aGVHD (P o0.0001) was the only clinical risk significantly associated with the development of SR aGVHD (Table 2A) . There was an association between severity of gut GVHD and steroid resistance. Forty-eight (51.6%) of 93 patients who had stage I/II GI GVHD had steroid refractory aGVHD. However, among 40 patients with stage III/IV GI GVHD 34 (85.0%) had steroid refractory aGVHD, OR 3.226, 95% CI 1.498-6.946; P = 0.001. We did not have GVHD grading available at onset to evaluate if the highrisk genotypes predicted for later GVHD progression.
Multivariate analysis for SR aGVHD Multivariate analysis was used to confirm the above findings. Two SNPs identified on univariate analysis, IL6 genotype of donor (rs1800797; P = 0.0068, OR 2.060, 95% CI 1.221-3.474) and IFNG genotype of donor (rs2069727; P = 0.0140, OR 2.087, 95% CI 1.161-3.751) along with gastrointestinal aGVHD (P o 0.0001, OR 3.148, 95% CI 1.857-5.284) were confirmed as independent risk factors (Table 2B ).
Calculation of risk scores and generation of risk model for SR aGVHD A score of 1 was assigned to each of the above risk factors as described in the Materials and Methods section and SR aGVHD was calculated based on these scores. Risk of SR aGVHD increased as scores increased (Figure 2) . Scores for the overall population are shown in Supplementary Figure 2 .
Next a risk model was generated by dividing patients in the training set into low (score 0, n = 74) vs high risk (scores 1-3; n = 106) as described in the Materials and Methods section. SR aGVHD was higher in high-risk group (65/106, 61.3%) than in a low-risk group (20/74, 27%; P o 0.0001, OR 4.28, 95% CI 2. 25-8.16 ). Improved predictive stratification of this risk model was successfully replicated in the validation set (n = 88; P = 0.0045, OR 3.74, 95% CI 1.47-9.52; Figure 3 ). Overall population also had higher Abbreviations: aGVHD = acute GVHD; CI = confidence interval; GI = gastrointestinal; OR = odds ratio; pts = patients; SNP = single nucleotide polymorphism; SR aGVHD = steroid refractory aGVHD. Abbreviations: aGVHD = acute GVHD; CI = confidence interval; GI = gastrointestinal; OR = odds ratio.
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(60%, n = 96) SR aGVHD in the high-risk group (n = 160), while lowrisk group (n = 108) had 26.8% (n = 29) SR aGVHD, Po0.0001 OR 4.09 95% CI 2.40-6.94 (Table 3) . Rates of SR aGVHD by this risk model for overall population are shown in Supplementary Figure 3 .
Sensitivity and specificity and AUC of model AUC was evaluated to measure model discrimination. In the training set a significant clinical risk factor (gastrointestinal GVHD), identified on univariate and confirmed on multivariate analysis, had an AUC of 0.627 and SNP risk factors (IL6 and IFNG) had an AUC of 0.699. In addition, when they were combined in the risk model, the AUC was 0.738 with sensitivity 76% and specificity 57%. Similarly in the validation set, the clinical risk factor (gastrointestinal GVHD) showed an AUC of 0.691 and SNP risk factors (IL6 and IFNG) had an AUC of 0.701 which improved to 0.773 with the risk model with sensitivity 77% and specificity 52%.
In the overall population, the clinical risk factor (gastrointestinal GVHD) had an AUC of 0.649 and SNP risk factors (IL6 and IFNG) had an AUC of 0.686. With the risk model, the AUC was noted to be 0.734 with sensitivity 74% and specificity 55%. Hence, with the risk model, specificity was enhanced while maintaining sensitivity, highlighting the improved prognostic stratification power of the model (Table 4 ; Supplementary Figure 5) . Risk model and overall response rate by days 28 and 56 after first-line GVHD treatment Overall response was then evaluated based on the risk model as described in the Materials and Methods section. At day 28 from the start of therapy among low-risk group patients alive at the time of day 28 assessment (n = 105), CR/PR was seen in 93% (n = 98), while in the high-risk group (n = 155), 75% (n = 116) had CR/PR, (P = 0.00002, OR 0.210, 95% CI 0.090-0.491). Day 56 CR/PR in low-risk group alive by day 56 (n = 99) was 94% (n = 93), while in the high-risk group (n = 143), 79% (n = 113) had CR/PR, (P = 0.002, OR 0.243, 95% CI 0.097-0.609; Figure 4) . Also, overall response rate in the training set by day 28 among low-risk group patients alive by day 28 (n = 72), CR/PR was seen in 94% (n = 68), while in the high-risk group (n = 105), 76% (n = 80) had CR/PR (P = 0.002, OR 0.188, 95% CI 0.062-0.568). At day 56 CR/PR in the low-risk group (n = 70) was 94% (n = 66), while in the high-risk group (n = 97), 79% (n = 77) had CR/PR (P = 0.007, OR 0.233, 95% CI 0.076-0.717; Supplementary Figures 4A and B) .
Similar pattern was seen in the validation set. Patients in the lowrisk group (n = 33) had a CR/PR of 91% (n = 30) at day 28, while in the high-risk group (n = 50) a CR/PR rate of 72% (n = 36) was observed (P = 0.037, OR 0.257, 95% CI 0.067-0.980). At day 56 CR/PR was 93% (n = 27) in the low-risk group patients (n = 29), while high-risk group Risk model and transplant outcomes including non-relapse, OS and GSS NRM of the overall population was 24.5% (95% CI 19.3-30.0) at 2 years. However, in the low-risk group NRM at 2 years was only 9% (95% CI 4.4-15.7) vs 34.7% (95% CI 27.1-42.4) in the high-risk group (P = 0.0001; Figure 5a ). OS of the whole population at 2 years was 58.6% (95% CI 52.1-64.4). When evaluated by risk model, low-risk group's OS at 2 years was 73% (95% CI 63.2-81.0) vs 49.0% (95% CI 40.8-56.7) in the high-risk group (P = 0.0006; Figure 5b) .
GSS of the whole population at 2 years was 72.2% (95% CI 65.9-77.5). However, in the low-risk group GSS at 2 years was 88.0% (95% CI 79.8-93.4) compared to 61.4% (95% CI 52.8-69.0) in the high-risk group (P = 0.0001; Figure 5c ). DISCUSSION SR aGVHD remains a major obstacle to successful allogeneic HCT. Non-clinical risk factors for the development of SR aGVHD have 
Set
Risk factors Variables AUC PPV (%) NPV (%) Sensitivity (%) Specificity (%) Abbreviations: aGVHD = acute GVHD; AUC = area under the curve; GI = gastrointestinal; NPV = negative predictive value; PPV = positive predictive value; SNP = single nucleotide polymorphism. not been extensively explored. The present study showed that donor IL6 (rs1800797) and IFNG (rs2069727) genotypes are major, independent risk factors associated with the development of SR aGVHD. We have generated a risk model using SNPs and clinical risk factors that can be used for prediction of SR aGVHD. This risk model is associated with long-term outcomes including OS, GSS and NRM. These findings make the risk model a potentially useful tool in clinical decision making at the onset of therapy for aGVHD. The donor IL6 genotype (rs1800797) was associated with SR aGVHD in the present study. The IL6 gene maps to chromosome 7p21. 30 IL6 is a cytokine that has been shown to be associated with inflammation and response to corticosteroids in several studies of diverse autoimmune diseases. [31] [32] [33] Serum IL6 levels have been reported to be increased in acute and chronic GVHD. 34, 35 In addition, G allele in a IL6 SNP has been shown to correlate with higher IL6 levels, 36 and is associated with increased risk of grade II-IV aGVHD.
37 IL6 can neutralize suppressive activity of regulatory T cells (T-regs), 38 hence enhancing GVHD. Blockade of IL6 signaling has been shown to increase absolute number of T-regs by augmentation of T-reg production 39 thereby decreasing the severity of GVHD. Tocilizumab, an anti-IL6 receptor antibody has been used in the treatment of steroid refractory GVHD. 40 IL6 gene polymorphisms have also been suggested to associate with response to steroids. 41 Hence, the possible mechanism may be an exaggerated immune response due to increased IL6 levels in the presence of this IL6 SNP, and the involvement of IL6 in resistance to steroids. The donor IFN-γ genotype (rs2069727) was also associated with SR aGVHD in this study. IFN-γ gene maps to chromosome 12p24. 42 IFN-γ has been implicated in the pathogenesis of aGVHD and response to steroids. [43] [44] [45] A murine model for GVHD has been shown to have abundant Interferon-γ in liver and gastrointestinal lesions. 46 IL-23 is a cytokine that has been demonstrated to be involved in the pathogenesis of GVHD. 47 IL-23 secretion by antigen-presenting cells increases production of IFN-γ by TH1 cells. 48 IFN-γ can cause direct effects on gastrointestinal tract GVHD. 49 Corticosteroid treatment results in decreased production of Interferon-γ in PBMC. 50 IFN-γ has also been implicated in steroid resistance in asthma by activation of MyD88-dependent pathways in macrophages. 51 Hence, the possible mechanism could be role of IFN-γ in downstream signaling of IL-23, hence contributing to pathogenesis of GVHD and involvement of IFN-γ in response to steroids. Surprisingly, only donor SNPs for IL6 and IFNG but not from recipient were significantly associated with increased risk of SR aGVHD, which means that donor level of IL6 and Interferon-γ plays a role in the pathogenesis of SR-GVHD, as suggested by other studies. 49 This suggests that this model can potentially be used to choose a donor when more than one donor is available in order to decrease the risk of SR aGVHD and improve outcome of HCT. There was no difference in risk of relapse among the different genotypes suggesting that there may not be any difference in graft vs disease effect in these donors. Importantly, we could identify risk factors for SR aGVHD in both clinical factors as well as SNPs. In addition, by generating the risk model we were able to predict risk of SR aGVHD more accurately. An AUC of 0.738 in the training set increased from 0.627 and AUC of 0.773 in the validation set increased from 0.627. Hence, this model may be beneficial in the clinical setting to predict SR aGVHD early. This can then potentially be used to stratify high-risk patients who may need to move to second-line agents or clinical trials for SR aGVHD.
The risk groups in the model showed excellent correlation with other clinical end points. When response rates at days 28 and 56 were evaluated, the low-risk group had higher CRs and PRs than the high-risk group in both training and validation cohorts (Figure 4 ). Similar correlation of risk groups with overall, GSS and NRM was also seen with the risk model (Figures 5a-c) .
Small sample size, retrospective data and clinical heterogeneity of the patients are limitations of this study and these data will need to be evaluated in a different dataset and/or prospective setting. Also, this is a single-center study and there are challenges with SNP association studies including heterogeneity of patient population. Hence, further studies in other independent cohorts are warranted perhaps using alternative GVHD prophylaxis strategies to better understand the mechanisms of SR aGVHD associating with various genotypes of donors and their association with steroid refractory GVHD.
In conclusion, a risk model using donor genotype for donor IL6 (rs1800797) and IFNG (rs2069727) along with presence of gastrointestinal GVHD can be used to predict the risk of developing steroid refractory GVHD. This risk model was found to be associated with response to steroid therapy, overall and GSS, and NRM, hence it can be employed as a tool in clinical decision making.
